Report for Q3 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688177)"Bio-Thera Solutions, Ltd."Report for Q3 2026
Filed with SSE · Stock code 688177 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- (688177)"Bio-Thera Solutions, Ltd."Announcement on Obtaining the Drug Registration Certificate for BAT2306 (Secukinumab Injection)
- Announcement on Attending the 2026 Collective Reception Day for Investors in Guangdong Jurisdiction and Interim Performance Briefing for Listed Companies in the Jurisdiction
- Announcement on Resignation of the Chief Financial Officer and Designation of the Chairman and the General Manager to Act as the Chief Financial Officer
- Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
- Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for Supplementary Application for Bevacizumab Injection (POBEVCY)
Later from Bio-Thera Solutions
- (688177)"Bio-Thera Solutions, Ltd."Announcement on Convening the Q3 2026 Performance Briefing
- (688177)"Bio-Thera Solutions, Ltd."Announcement on the Latest Business Development of BAT1706 (Bevacizumab)
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions